Methods of treating cancer with farnesyltransferase inhibitors
The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
1. A method of treating an angioimmunoblastic T-cell lymphoma (AITL) in a subject, comprising administering to the subject tipifarnib at a dose of 200-1200 mg twice a day on days 1-7 of a 28-day treatment cycle.
2. The method of claim 1 , wherein the AITL is relapsed or refractory AITL.
3. The method of claim 1 , wherein the tipifarnib is administered orally.
4. The method of claim 1 , wherein the tipifarnib is selectively administered to the subject on the basis that the subject has a tumor of AITL histology.
5. The method of claim 1 , wherein the subject having AITL has been diagnosed with AITL.
6. The method of claim 1 , wherein the tipifarnib is administered at a dose of 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 765, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1125, 1150, 1175, or 1200 mg twice a day.
7. The method of claim 1 , wherein the tipifarnib is administered at a dose of 300-900 mg twice a day.
8. The method of claim 7 , wherein the tipifarnib is administered at a dose of 300 mg, 600 mg, or 900 mg twice a day.
9. The method of claim 1 , further comprising administering a therapeutically effective amount of a second active agent or a support care therapy.
10. A method of treating an angioimmunoblastic T-cell lymphoma (AITL) in a subject, comprising administering to the subject tipifarnib at a dose of 200-1200 mg twice a day in alternate weeks in repeated 4 week treatment cycles.
11. The method of claim 10 , wherein the tipifarnib is administered on days 1-7 and 15-21 of a 28-day treatment cycle.
12. The method of claim 11 , wherein the AITL is relapsed or refractory AITL.
13. The method of claim 11 , wherein the tipifarnib is administered orally.
14. The method of claim 11 , wherein the tipifarnib is selectively administered to the subject on the basis that the subject has a tumor of AITL histology.
15. The method of claim 11 , wherein the subject having AITL has been diagnosed with AITL.
16. The method of claim 11 , wherein the tipifarnib is administered at a dose of 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 765, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1125, 1150, 1175, or 1200 mg twice a day.
17. The method of claim 11 , wherein the tipifarnib is administered at a dose of 300-900 mg twice a day.
18. The method of claim 17 , wherein the tipifarnib is administered at a dose of 900 mg twice a day.
19. The method of claim 17 , wherein the tipifarnib is administered at a dose of 600 mg twice a day.
20. The method of claim 17 , wherein the tipifarnib is administered at a dose of 300 mg twice a day.
21. The method of claim 17 , wherein the AITL is relapsed or refractory AITL.
22. The method of claim 17 , wherein the tipifarnib is administered orally.
23. The method of claim 17 , further comprising administering a therapeutically effective amount of a second active agent or a support care therapy.
24. A method of treating an angioimmunoblastic T-cell lymphoma (AITL) in a subject, comprising administering to the subject tipifarnib at a dose of 200-1200 mg twice a day for 3 out of 4 weeks in repeated 4 week treatment cycles.
25. The method of claim 24 , wherein the tipifarnib is administered on days 1-21 of a 28-day treatment cycle.
26. The method of claim 24 , wherein the AITL is relapsed or refractory AITL.
27. The method of claim 24 , wherein the tipifarnib is administered orally.
28. The method of claim 24 , wherein the tipifarnib is selectively administered to the subject on the basis that the subject has a tumor of AITL histology.
29. The method of claim 24 , wherein the subject having AITL has been diagnosed with AITL.
30. The method of claim 24 , wherein the tipifarnib is administered at a dose of 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 765, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1125, 1150, 1175, or 1200 mg twice a day.
31. The method of claim 24 , wherein the tipifarnib is administered at a dose of 300-900 mg twice a day.
32. The method of claim 31 , wherein tipifarnib is administered at a dose of 300 mg twice a day.
33. The method of claim 31 , wherein the AITL is relapsed or refractory AITL.
34. The method of claim 31 , wherein the tipifarnib is administered orally.
35. The method of claim 24 , further comprising administering a therapeutically effective amount of a second active agent or a support care therapy.
36. The method of claim 31 , wherein the tipifarnib is administered on days 1-21 of a 28-day treatment cycle.
37. The method of claim 32 , wherein the tipifarnib is administered on days 1-21 of a 28-day treatment cycle.
38. The method of claim 36 , wherein the AITL is relapsed or refractory AITL.
39. The method of claim 37 , wherein the AITL is relapsed or refractory AITL.